These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

256 related items for PubMed ID: 23807172

  • 21. Pristimerin synergistically sensitizes conditionally reprogrammed patient derived-primary hepatocellular carcinoma cells to sorafenib through endoplasmic reticulum stress and ROS generation by modulating Akt/FoxO1/p27kip1 signaling pathway.
    Tang Y, Chen J, Li J, Zheng Y, Zhong X, Huang S, Chen B, Peng B, Zou X, Chen X.
    Phytomedicine; 2021 Jun; 86():153563. PubMed ID: 33951569
    [Abstract] [Full Text] [Related]

  • 22. Combining celecoxib with sorafenib synergistically inhibits hepatocellular carcinoma cells in vitro.
    Morisaki T, Umebayashi M, Kiyota A, Koya N, Tanaka H, Onishi H, Katano M.
    Anticancer Res; 2013 Apr; 33(4):1387-95. PubMed ID: 23564777
    [Abstract] [Full Text] [Related]

  • 23. Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling.
    Hsu FT, Liu YC, Chiang IT, Liu RS, Wang HE, Lin WJ, Hwang JJ.
    Int J Oncol; 2014 Jul; 45(1):177-88. PubMed ID: 24807012
    [Abstract] [Full Text] [Related]

  • 24. Synergistic interaction between the HDAC inhibitor, MPT0E028, and sorafenib in liver cancer cells in vitro and in vivo.
    Chen CH, Chen MC, Wang JC, Tsai AC, Chen CS, Liou JP, Pan SL, Teng CM.
    Clin Cancer Res; 2014 Mar 01; 20(5):1274-1287. PubMed ID: 24520095
    [Abstract] [Full Text] [Related]

  • 25. Synergistic growth inhibition by sorafenib and vitamin K2 in human hepatocellular carcinoma cells.
    Zhang Y, Zhang B, Zhang A, Zhao Y, Zhao J, Liu J, Gao J, Fang D, Rao Z.
    Clinics (Sao Paulo); 2012 Sep 01; 67(9):1093-9. PubMed ID: 23018309
    [Abstract] [Full Text] [Related]

  • 26. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
    He C, Dong X, Zhai B, Jiang X, Dong D, Li B, Jiang H, Xu S, Sun X.
    Oncotarget; 2015 Oct 06; 6(30):28867-81. PubMed ID: 26311740
    [Abstract] [Full Text] [Related]

  • 27. The retinoblastoma (Rb) protein regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma cells.
    Louandre C, Marcq I, Bouhlal H, Lachaier E, Godin C, Saidak Z, François C, Chatelain D, Debuysscher V, Barbare JC, Chauffert B, Galmiche A.
    Cancer Lett; 2015 Jan 28; 356(2 Pt B):971-7. PubMed ID: 25444922
    [Abstract] [Full Text] [Related]

  • 28. Antiproliferative effects of sorafenib and pegylated IFN‑α2b on human liver cancer cells in vitro and in vivo.
    Kusano H, Ogasawara S, Akiba J, Nakayama M, Ueda K, Yano H.
    Int J Oncol; 2013 Jun 28; 42(6):1897-903. PubMed ID: 23588838
    [Abstract] [Full Text] [Related]

  • 29. Cyclin E1 Inhibition can Overcome Sorafenib Resistance in Hepatocellular Carcinoma Cells Through Mcl-1 Suppression.
    Hsu C, Lin LI, Cheng YC, Feng ZR, Shao YY, Cheng AL, Ou DL.
    Clin Cancer Res; 2016 May 15; 22(10):2555-64. PubMed ID: 26603262
    [Abstract] [Full Text] [Related]

  • 30. Deciphering the molecular mechanism of tetrandrine in inhibiting hepatocellular carcinoma and increasing sorafenib sensitivity by combining network pharmacology and experimental evaluation.
    Niu B, Wei S, Sun J, Zhao H, Wang B, Chen G.
    Pharm Biol; 2022 Dec 15; 60(1):75-86. PubMed ID: 34962429
    [Abstract] [Full Text] [Related]

  • 31. Inhibition of the Wnt/β-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma.
    Lin HH, Feng WC, Lu LC, Shao YY, Hsu CH, Cheng AL.
    Cancer Lett; 2016 Oct 10; 381(1):58-66. PubMed ID: 27431312
    [Abstract] [Full Text] [Related]

  • 32. Recombinant human acid sphingomyelinase as an adjuvant to sorafenib treatment of experimental liver cancer.
    Savić R, He X, Fiel I, Schuchman EH.
    PLoS One; 2013 Oct 10; 8(5):e65620. PubMed ID: 23724146
    [Abstract] [Full Text] [Related]

  • 33. YC-1 enhances the anti-tumor activity of sorafenib through inhibition of signal transducer and activator of transcription 3 (STAT3) in hepatocellular carcinoma.
    Kong J, Kong F, Gao J, Zhang Q, Dong S, Gu F, Ke S, Pan B, Shen Q, Sun H, Zheng L, Sun W.
    Mol Cancer; 2014 Jan 13; 13():7. PubMed ID: 24418169
    [Abstract] [Full Text] [Related]

  • 34. PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.
    Gedaly R, Angulo P, Hundley J, Daily MF, Chen C, Koch A, Evers BM.
    Anticancer Res; 2010 Dec 13; 30(12):4951-8. PubMed ID: 21187475
    [Abstract] [Full Text] [Related]

  • 35. Allosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma.
    Schmieder R, Puehler F, Neuhaus R, Kissel M, Adjei AA, Miner JN, Mumberg D, Ziegelbauer K, Scholz A.
    Neoplasia; 2013 Oct 13; 15(10):1161-71. PubMed ID: 24204195
    [Abstract] [Full Text] [Related]

  • 36. Sorafenib enhances proteasome inhibitor-induced cell death via inactivation of Akt and stress-activated protein kinases.
    Honma Y, Shimizu S, Takehara T, Harada M.
    J Gastroenterol; 2014 Mar 13; 49(3):517-26. PubMed ID: 23543326
    [Abstract] [Full Text] [Related]

  • 37. Fisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells.
    Pal HC, Baxter RD, Hunt KM, Agarwal J, Elmets CA, Athar M, Afaq F.
    Oncotarget; 2015 Sep 29; 6(29):28296-311. PubMed ID: 26299806
    [Abstract] [Full Text] [Related]

  • 38. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
    Han P, Li H, Jiang X, Zhai B, Tan G, Zhao D, Qiao H, Liu B, Jiang H, Sun X.
    Mol Oncol; 2017 Mar 29; 11(3):320-334. PubMed ID: 28164434
    [Abstract] [Full Text] [Related]

  • 39. Synergistic Antitumor Effect of Sorafenib in Combination with ATM Inhibitor in Hepatocellular Carcinoma Cells.
    Liu J, Liu Y, Meng L, Ji B, Yang D.
    Int J Med Sci; 2017 Mar 29; 14(6):523-529. PubMed ID: 28638267
    [Abstract] [Full Text] [Related]

  • 40. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
    Liang Y, Zheng T, Song R, Wang J, Yin D, Wang L, Liu H, Tian L, Fang X, Meng X, Jiang H, Liu J, Liu L.
    Hepatology; 2013 May 29; 57(5):1847-57. PubMed ID: 23299930
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.